Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

The Journal of antimicrobial chemotherapy - 1 Jun 2008

Masquelier B, Assoumou K L, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin A G, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D

Abstract excerpt

BACKGROUND: We developed clinically relevant genotypic scores for resistance to fosamprenavir/ritonavir in HIV-1 protease inhibitor (PI)-experienced patients. METHODS: PI-experienced patients with virological failure receiving fosamprenavir/ritonavir as the sole PI for at least 3 months and with detectable fosamprenavir plasma levels were included. The impact of baseline protease mutations on virological response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to HIV Protease Inhibitors

Share to Organophosphates

Share to Ritonavir

Share to Sulfonamides

Share to Viral Load

Source

Identifiers

PMID: 18390885
DOI: 10.1093/jac/dkn127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.PMID 18390885Read ↗

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.Semantic proximity Read ↗

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.Semantic proximity Read ↗

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.Semantic proximity Read ↗

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.Semantic proximity Read ↗

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.Semantic proximity Read ↗

Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.Semantic proximity Read ↗

Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.